HBV Reactivation and Lamivudine Treatment in Patients with Lymphoma Undergoing Chemotherapy: Four Cases

Flora Infeksiyon Hastalıkları ve Klinik Mikrobiyoloji Dergisi. 2006;11(4):205-209

 

Journal Homepage

Journal Title: Flora Infeksiyon Hastalıkları ve Klinik Mikrobiyoloji Dergisi

ISSN: 1300-932X (Print)

Publisher: Bilimsel Tip Yayinevi

LCC Subject Category: Medicine: Internal medicine: Infectious and parasitic diseases | Science: Microbiology

Country of publisher: Turkey

Language of fulltext: English, Turkish

Full-text formats available: PDF

 

AUTHORS

İlhan AFŞAR (Atatürk Eğitim ve Araştırma Hastanesi, Mikrobiyoloji Laboratuvarı)
Mustafa PEHLİVAN (Atatürk Eğitim ve Araştırma Hastanesi, Hematoloji Kliniği, İZMİR)
Aslı Gamze ŞENER (Atatürk Eğitim ve Araştırma Hastanesi, Mikrobiyoloji Laboratuvarı)
Metin TÜRKER (Atatürk Eğitim ve Araştırma Hastanesi, Mikrobiyoloji Laboratuvarı)

EDITORIAL INFORMATION

Double blind peer review

Editorial Board

Instructions for authors

Time From Submission to Publication: 2 weeks

 

Abstract | Full Text

Chronic hepatitis patients undergoing immunosupressive or cytotoxic treatment may develop acute hepatitis or fulminant hepatitis due to reactivation of hepatitis B virus (HBV) and these patients may lose their lives after their treatments are discontinued. Lamivudine which was the first oral drug developed against chronic hepatitis in 1999 is a nucleoside analogue, and it shows its effect by inhibiting reverse transcriptase enzyme. Lamivudine has also been shown to be relatively safe for its side effects when compared with the interferon treatment. In this article we reported the HBV reactivation in four cases of HBV carriers with lymphoma to whom chemotherapy was applied, and the effectiveness and safety of the lamivudine treatment.